Tilray Medical Supports Scientific Study on Fibromyalgia With Positive Outcomes: Effectiveness of Cannabinoids Treatment in Pain Management and Other Fibromyalgia-Associated Symptoms
September 09 2024 - 7:00AM
UK Regulatory
Tilray Medical Supports Scientific Study on Fibromyalgia With
Positive Outcomes: Effectiveness of Cannabinoids Treatment in Pain
Management and Other Fibromyalgia-Associated Symptoms
LISBON, Portugal, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Tilray
Medical, a division of Tilray Brands, Inc. (“Tilray”) (Nasdaq:
TLRY; TSX: TLRY) and a global leader in medical cannabis,
empowering the therapeutic alliance between patients and healthcare
practitioners to make informed individualized health decisions,
today announced a new scientific publication supported by
Tilray Medical titled, Treatment in Pain
Management and Other Fibromyalgia-Associated Symptoms: A Case
Series (TOMAS). The study examines
the real-world impact of cannabinoid treatments on patients with
fibromyalgia (FM) under the guidance of healthcare
providers.
The TOMAS study, consisting of patients with an average age of
52 years, examined the effects of Tilray Dried Flower THC18 on
chronic pain and other FM-associated symptoms. The study sheds
light on the impact of cannabinoids on health outcomes, with a
particular focus on pain, sleep, and quality of life.
With medical cannabis guidance and supervision, the study
demonstrated improvements in pain scores, sleep quality, and
overall quality of life for fibromyalgia patients. Moreover, there
was a notable reduction in co-medication, suggesting that
cannabinoids may be an effective and cost-efficient treatment
option for this population. The results of this study provide
valuable insights for the medical and scientific community on the
use of cannabinoids in managing chronic pain and improving the
quality of life for patients with fibromyalgia.
José Tempero, Tilray’s Medical Director, commented, "The
findings of this study are encouraging and provide hope for
fibromyalgia patients who are seeking effective treatments. At
Tilray, we are committed to conducting comprehensive scientific
research that ensures our treatments are based on evidence and can
improve patient care. We believe that these results represent a
significant step forward in advancing the understanding of the
therapeutic potential of cannabinoids and their role in managing
chronic pain."
Denise Faltischek, Chief Strategy Officer and Head of
International at Tilray Brands, said, "Tilray’s involvement in this
study underscores our unwavering commitment to advancing medical
research and unlocking the full therapeutic potential of medical
cannabis. The TOMAS study and its positive outcomes for patients
with fibromyalgia, highlights the potential of cannabinoids as a
safe and effective treatment option for patients with chronic pain
and associated symptoms. Tilray Medical remains committed to
advancing the science of medical cannabis and empowering patients
and healthcare practitioners with the knowledge they need to make
informed decisions about their health."
Tilray Medical’s mission is to continue transforming lives and
fostering dignity for patients in need through access to medical
cannabis. Today, Tilray is a leading provider of EU-GMP certified
medical cannabis products in over 20 countries with a comprehensive
portfolio of THC and CBD products. Tilray has supported medical
trials globally, across Europe, Canada, the United States,
Australia, and Latin America, studying the efficacy of medical
cannabis as a treatment for indications including pediatric
epilepsy, refractory pediatric epilepsy, cancer-induced nausea and
vomiting, HIV, essential tremor, breast cancer disorders,
post-traumatic stress disorder, and alcohol use disorders.
About Tilray Medical
Tilray Medical is dedicated to transforming lives and fostering
dignity for patients in need through safe and reliable access to a
global portfolio of medical cannabis brands, including Tilray,
Aphria, Broken Coast, Symbios and Navcora. Tilray grew from being
one of the first companies to become an approved licensed producer
of medical cannabis in Canada to building the first GMP-certified
cannabis production facilities in Europe, first in Portugal and
later in Germany. Today, Tilray Medical is one of the largest
suppliers of medical cannabis to patients, physicians, hospitals,
pharmacies, researchers, and governments, in 20 countries and
across five continents.
For more information on Tilray Medical, visit Tilray Medical
Europe, Tilray Medical Canada, and Tilray Medical
Australia-New Zealand.
About Tilray Brands
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a
leading global lifestyle and consumer packaged goods company with
operations in Canada, the United States, Europe, Australia, and
Latin America that is leading as a transformative force at the
nexus of cannabis, beverage, wellness, and entertainment, elevating
lives through moments of connection. Tilray’s mission is to be a
leading premium lifestyle company with a house of brands and
innovative products that inspire joy and create memorable
experiences. Tilray’s unprecedented platform supports over 40
brands in over 20 countries, including comprehensive cannabis
offerings, hemp-based foods, and craft beverages.
For more information on how we are elevating lives through
moments of connection, visit Tilray.com and follow @Tilray on all
social platforms.
Contacts:
Tilray Brands: news@tilray.com
Investors: investors@tilray.com
Tilray Brands (TG:2HQ)
Historical Stock Chart
From Nov 2024 to Dec 2024
Tilray Brands (TG:2HQ)
Historical Stock Chart
From Dec 2023 to Dec 2024